Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2632 -0.0178 (-6.33%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stocks That Hit 52-Week Lows On Monday ↗

May 23, 2022

On Monday, 149 companies reached new 52-week lows.

Via Benzinga

7 Cheap Biotech Stocks to Buy Now ↗

May 19, 2022

These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.

Via InvestorPlace

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer

May 02, 2022

Via Investor Brand Network

Topics Intellectual Property

Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou ↗

April 16, 2022

Deals, financings, trials and approvals in biotech in China this week.

Via Talk Markets

VistaGen Appoints Reid Adler as Chief Legal Officer

May 02, 2022

From VistaGen Therapeutics, Inc.

Via Business Wire

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses

April 21, 2022

Via Investor Brand Network

VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses

April 21, 2022

From VistaGen Therapeutics, Inc.

Via Business Wire

Recap: VistaGen Therapeutics Q3 Earnings ↗

February 10, 2022

VistaGen Therapeutics (NASDAQ:VTGN) reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 10, 2022 ↗

February 10, 2022

Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.

Via Benzinga

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial

April 12, 2022

Via Investor Brand Network

VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B

April 12, 2022

From VistaGen Therapeutics, Inc.

Via Business Wire

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference

March 24, 2022

Via Investor Brand Network

Stocks That Hit 52-Week Lows On Tuesday ↗

March 15, 2022

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 14, 2022

On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 07, 2022

On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 17, 2022

Gainers Creative Medical Tech (NASDAQ:CELZ

Via Benzinga

VistaGen Therapeutics Earnings Perspective: Return On Capital Employed ↗

February 14, 2022

According to data from Benzinga Pro, during Q3, VistaGen Therapeutics's (NASDAQ:VTGN) reported sales totaled $357.90 thousand. Despite a 17.66% increase in earnings, the company posted a loss of $10.54...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

February 22, 2022

During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to...

Via Benzinga

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update

February 11, 2022

Via Investor Brand Network

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call

February 07, 2022

Via Investor Brand Network

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18

November 16, 2021

Via Investor Brand Network

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights

November 11, 2021

Via Investor Brand Network

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update

November 04, 2021

Via Investor Brand Network

VistaGen Therapeutics Inc. Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial ↗

October 14, 2021

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and...

Via Benzinga

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial

October 14, 2021

Via Investor Brand Network

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity

October 05, 2021

Via Investor Brand Network

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 26, 2021

Gainers MorphoSys (NASDAQ:MOR) stock move...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 13, 2021

Gainers Cellect Biotechnology (NASDAQ:APOP

Via Benzinga

Recap: VistaGen Therapeutics Q1 Earnings ↗

August 12, 2021

Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the...

Via Benzinga

Looking Into VistaGen Therapeutics's Return On Capital Employed ↗

July 13, 2021

In Q4, VistaGen Therapeutics (NASDAQ:VTGN) posted sales of $441.90 thousand. Earnings were up 17.36%, but VistaGen Therapeutics still reported an overall loss of $6.22 million....

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.